Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Aranesp darbepoetin alfa regulatory update

AMGN formally requested that the Centers for Medicare & Medicaid Services (CMS) reconsider its final National Coverage Determination (NCD) on

Read the full 205 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE